Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
45.85
-1.60 (-3.37%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Supernus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Supernus Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $61.75. The average 1-year stock price forecast is 34.68% higher than the current stock price, while the lowest is $55 (+19.96%) and the highest is $67 (+46.13%).
Price Target: $61.75 (+34.68%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Supernus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Maintains $65 | Buy | Maintains | $65 | +41.77% | Aug 4, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $66 | Buy | Reiterates | $66 | +43.95% | Jul 27, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $63 | Buy | Maintains | $63 | +37.40% | Jul 13, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $65 | Buy | Maintains | $65 | +41.77% | Jul 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $63 → $67 | Buy | Maintains | $63 → $67 | +46.13% | Jul 9, 2026 |
Financial Forecast
Revenue This Year
885.80M
from 718.95M
Increased by 23.21%
Revenue Next Year
1.37B
from 885.80M
Increased by 54.85%
EPS This Year
2.57
from 2.40
Increased by 7.09%
EPS Next Year
4.46
from 2.57
Increased by 73.88%
EPS and Forward PE are based on non-GAAP adjusted numbers.